- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07479043
급성 호흡 곤란 증후군(ARDS)으로 진단된 환자에서 실험적 제대혈 유래 중간엽 줄기세포 치료제인 JadiCell™의 안전성과 잠재적 치료 활성을 평가하기 위한 연구.
JadiCell™ (제대혈 유래 중간엽 줄기세포)의 급성 호흡곤란 증후군(ARDS) 치료에 관한 3상 임상 연구
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.
연구 개요
상태
상세 설명
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammatory lung injury, impaired oxygen exchange, and high mortality. Current treatments are primarily supportive and include mechanical ventilation and intensive care management.
JadiCell™ is an investigational cellular therapy derived from human umbilical cord tissue. These cells possess immunomodulatory and regenerative properties and may reduce inflammatory lung injury through paracrine signaling, immune regulation, and tissue repair mechanisms.
Following intravenous administration, mesenchymal stem cells are known to localize within the pulmonary microvasculature where they interact with immune cells and injured lung tissue.
This study will evaluate the safety and potential clinical effects of intravenous JadiCell administration in patients with ARDS.
연구 유형
등록 (추정된)
단계
- 3단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients currently hospitalized
- Laboratory confirmation of ARDS
- Aged between 18 and 80 years
- Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
- SpO2 <94% on room air requiring supplemental oxygen above baseline
- PaO2/FiO2 <300 mmHg
- Bilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan
- Requiring one of the following ï High Flow Oxygen Therapy ï Non-invasive Positive Pressure Ventilation (NIPPV, e.g. BiPAP and CPAP) ï Invasive Mechanical Ventilation (INV = intubated)
Exclusion Criteria:
- Greater than 96 h since hospitalization at the time of enrollment
- Greater than 48 h since intubation at the time of enrollment
- A previous MSC infusion not related to this trial
- History of Pulmonary Hypertension (WHO Class III/IV)
- History of left atrial hypertension or decompensated left heart failure.
- Pregnant or lactating patient
- Unstable arrhythmia
- Patients currently receiving immunosuppression with exception of up to 10 mg Prednisone equivalents daily
- Patients currently receiving chronic dialysis
- Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO)
- Presence of any active malignancy (except non-melanoma skin cancer)
- Moderate to severe liver disease (AST and ALT >5 X ULN)
- Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen at rest
- Septic Shock (with >1 vasopressor)
- Multi-organ failure
- Not expected to survive > 48 hours
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment
Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC. |
Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC. |
|
위약 비교기: Control
Controls will receive two infusions of vehicle solution. |
Subjects in the control group will be treated with two IV infusions of vehicle solution. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Alive and Free of Respiratory Failure
기간: 60 days
|
The proportion of participants who are alive and free of respiratory failure following treatment with UC-MSC therapy. |
60 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
1. All-Cause Mortality
기간: 60 Days
|
Number of Participants Who Died (All-Cause Mortality) |
60 Days
|
|
2. Survival Status
기간: 31 Days
|
Number of Participants Alive at Day 31 |
31 Days
|
|
3. Incidence of Serious Adverse Events (SAEs)
기간: 31 Days
|
Number of Participants Experiencing Serious Adverse Events (SAEs) |
31 Days
|
|
4. Serious Adverse Event-Free Survival
기간: 31 Days
|
Number of Participants Alive Without Serious Adverse Events |
31 Days
|
|
5. Time to Clinical Recovery
기간: Up to 60 Days
|
Time to Clinical Recovery (Days) |
Up to 60 Days
|
|
6. Time to Oxygen Requirement ≤ 40%
기간: Up to 60 Days
|
Time to Oxygen Requirement ≤ 40% (Days) |
Up to 60 Days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .